Connective Tissue Disease Associated With Interstitial Lung Disease (CTD-ILD) Epidemiology

Key Highlights

• Connective Tissue Disease Associated With Interstitial Lung Disease (CTD-ILD) Diagnosed Prevalent Cases are anticipated to rise due to improved imaging methods and diagnostic tools enabling earlier detection of CTD-ILD cases, further increasing prevalence estimates.
• Within the 7MM and China, China exhibited the highest number of Diagnosed Prevalent Cases, followed by the US and Japan, whereas Spain reported the lowest. The projected trend for the forecast period indicates an upward trajectory in the 7MM and China.
• Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), dermatomyositis (DM) and polymyositis (PM), ankylosing spondylitis (AS), Sjogren’s syndrome (SS), and other connective tissue diseases (CTDs) are among those displaying characteristics of interstitial lung disease (ILD). Of these, the highest prevalence was estimated in pSS-ILD in the 7MM in 2022.

DelveInsight’s “Connective Tissue Disease Associated With Interstitial Lung Disease (CTD-ILD) – Epidemiology – 2034” report delivers an in-depth understanding of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), historical and forecasted epidemiology of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan
• China

Study Period: 2021-2034

Connective Tissue Disease Associated With Interstitial Lung Disease (CTD-ILD) Disease Understanding

Connective Tissue Disease Associated With Interstitial Lung Disease (CTD-ILD) Overview

Connective Tissue Diseases (CTDs) encompass systemic autoimmune disorders triggered by heightened immune-driven inflammation that targets the body’s connective tissues. This is observed in conditions like rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS), and idiopathic inflammatory myopathies such as dermatomyositis (DM) and polymyositis (PM), along with systemic sclerosis (SSc) and mixed connective tissue disease (MCTD). CTDs can result in serious complications affecting the pulmonary system, including bleeding, inflammation, and fibrosis in the spaces between lung air sacs and blood vessels. This inflammation and fibrosis resemble Interstitial Lung Disease (ILD), and in cases where CTDs lead to ILD (CTD-ILD), it can hinder oxygen absorption in the lungs, causing symptoms like breathlessness, cough, and fatigue.

Connective Tissue Disease Associated With Interstitial Lung Disease (CTD-ILD) Diagnosis

Diagnosing CTD-associated Interstitial Lung Diseases (CTD-ILDs) relies on clinical and radiological evidence, often complemented by autoantibodies; conventional chest X-rays tend to lack sensitivity. The benchmark for identifying ILD is high-resolution CT (HRCT). Diagnosing a particular CTD necessitates adherence to classification criteria specific to that particular disorder. Diagnosing CTD-ILD poses challenges due to varied clinical presentations, potential overlap with other conditions, lack of specific biomarkers, and atypical radiological patterns. Limited access to high-resolution CT scans and evolving diagnostic criteria complicate accurate identification.

Further details related to disease and its diagnosis are provided in the report…

Connective Tissue Disease Associated With Interstitial Lung Disease (CTD-ILD) Epidemiology

Utilizing the patient-based model, the Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Interstitial Lung Disease (ILD), Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD), Diagnosed Prevalent Cases of CTD-ILD, which is further segmented by type in the 7MM and China covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China from 2021 to 2034.

• The total Diagnosed Prevalent Cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) in the 7MM and China comprised approximately 1 million cases in 2022 and are projected to increase during the forecast period (2025-2034).
• The total prevalent cases of Interstitial Lung Disease (ILD) in the 7MM and China were more than 5 million, of which around 4 million cases were diagnosed.
• Among the Diagnosed Prevalent Cases of ILD in both the 7MM and China, approximately 28% were linked to CTD, leading to an estimated diagnosed prevalence of 1 million cases of CTD-ILD in 2022.
• Among the 7MM and China, China exhibited the highest diagnosed prevalent CTD-ILD cases, surpassing approximately 0.7 million in 2022. According to DelveInsight’s assessments, this country alone represents almost 73% of the combined total diagnosed prevalent CTD-ILD cases, followed by the United States, contributing about 12% of the total CTD-ILD cases.
• In 2022, the type-specific distribution of Diagnosed Prevalent Cases of CTD-ILD showed SSc-ILD, RA-ILD, pSS-ILD, SLE-ILD, PM/DM-ILD, and other CTD-ILDs comprised 7%, 22%, 39%, 4%, 4%, and 23% cases, respectively in the 7MM.
• EU4 and the UK accounted for nearly 92,000 Diagnosed Prevalent Cases of CTD-ILD in 2022. Of these cases, the UK accounted for the highest number of Diagnosed Prevalent Cases of CTD-ILD among EU4 and the UK.
• Japan accounted for 6% of the total Diagnosed Prevalent Cases of CTD-ILD in the 7MM and China in 2022.

KOL Views

To keep up with current epidemiology trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) evolving advancements in diagnosis, disease awareness, increasing cases, and challenges, including Pulmonologists, HCPs, Physicians, and others.

Delveinsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the University of Texas, Houston, TX, US; College of Medicine & Health, University of Exeter, UK; Rheumatology, First Hospital of Jilin University, Changchun, China; Graduate School of Medical Sciences, Kyushu University; and others were contacted. Their opinion helps understand and validate current and future epidemiological patterns of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD).

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), explaining its causes, signs and symptoms, pathogenesis, and diagnosis.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and diagnostic guidelines has been provided.
• The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journey in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Connective Tissue Disease Associated With Interstitial Lung Disease (CTD-ILD) Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Total Prevalent Cases of Interstitial Lung Disease (ILD)
• Total Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD)
• Total Diagnosed Prevalent Cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD)
• Type-specific Diagnosed Prevalent Cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD)

Connective Tissue Disease Associated With Interstitial Lung Disease (CTD-ILD) Report Key Strengths

• Ten Years Forecast
• The 7MM Coverage
• Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) Epidemiology Segmentation

Connective Tissue Disease Associated With Interstitial Lung Disease (CTD-ILD) Report Assessment

• Current Diagnostic Practices

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD)? What growth opportunities will be across the 7MM concerning the patient population with Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD)?
• What is the historical and forecasted Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What are the diagnosed prevalence rates in the US, European countries, and Japan? Why are Connective Tissue Diseases associated with Interstitial Lung Disease (CTD-ILD) patients not diagnosed efficiently?
• Which etiology accounts for the largest proportion of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) patients?
• At what CAGR is the population expected to grow across the 7MM forecast period (2025-2034)?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) Diagnosed Prevalent Cases based on types in varying geographies over the coming years.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• The Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) epidemiology report and model was written and developed by Masters and PhD level epidemiologists.
• Develop business strategies by understanding the trends shaping and driving the 7MM Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) epidemiology forecast.

Frequently Asked Questions

1. Which country had the highest Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) cases in 2022? Are the cases expected to increase or decrease?

The US had the highest Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) cases in 2022. The cases are expected to increase during the study period.

2. Why is CTD-ILD significant?

CTD-ILD can lead to serious lung complications, causing breathlessness, coughing, and fatigue. It is a major contributor to morbidity and mortality in individuals with autoimmune disorders.

3. What does the epidemiological forecast report cover?

The report provides insights into the prevalence and projected trends of CTD-ILD, including its association with specific connective tissue diseases across various regions.

4. Which regions are included in the report?

The report likely covers a range of regions, potentially including the 7MM countries and China.

5. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. Using mathematical models, it is then analyzed to calculate disease rates, identify trends, and project future disease burdens.